POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

Reduction of Visceral Fat May Significantly Reduce Intestinal Tumors

Share this article:
First Causal Evidence of Visceral Fat-Cancer Connection
First Causal Evidence of Visceral Fat-Cancer Connection

(HealthDay News) -- Reduction of visceral fat through surgery or diet reduces intestinal tumors in mice, with clear differences between males and females, according to a study published in the March issue of Cancer Prevention Research.

To examine the role of visceral fat in intestinal tumorigenesis, Derek M. Huffman, Ph.D., from the Albert Einstein College of Medicine in Bronx, N.Y., and colleagues treated mice genetically prone to develop intestinal cancer (Apc1638/N+) with a sham surgery and ad libitum feeding, visceral fat removal and ad libitum feeding, or sham surgery and caloric restriction to reduce visceral fat.

The researchers found that visceral fat reduction either through surgery or caloric restriction was effective in significantly reducing intestinal tumors, although only caloric restriction significantly improved survival. In females, only visceral fat removal was effective in reducing intestinal tumors, although visceral fat reduction either through surgery and caloric restriction improved survival. In males, only caloric restriction was effective in reducing intestinal tumors. Caloric restriction was associated with positive metabolic adaptations, while visceral fat removal was not associated with similar changes.

"In conclusion, these data provide the first causal evidence linking visceral fat to intestinal cancer risk, and suggest that factors, other than known metabolic mediators, may impact tumor development," Huffman and colleagues write.

Abstract
Full Text

This article originally appeared here.
Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in General Oncology News

Nearly 1 in 20 Patients with Cancer Die Within Month of Surgery

Nearly 1 in 20 Patients with Cancer Die ...

Lack of access to quality care a major factor in these cancer deaths.

Researchers Discover VEGF Contributes to Cancer-Associated Anemia

Researchers Discover VEGF Contributes to Cancer-Associated Anemia

Researchers discovered how cancer affects a person's blood count and bone marrow characteristics.

Akynzeo Approved for Chemotherapy-Induced Nausea, Vomiting

Akynzeo Approved for Chemotherapy-Induced Nausea, Vomiting

The FDA has approved Akynzeo (netupitant and palonosetron; Eisai) to treat nausea and vomiting in patients undergoing chemotherapy.